Medpace Holdings, Inc. (MEDP)

In the past six months, Medpace's stock price has been impacted by several events. On February 9, 2026, the stock price dropped nearly 16% after the company reported its fourth-quarter 2025 financial results, which included a book-to-bill ratio of 1.04, falling short of its guidance of 1.15. On April 23, 2026, the company announced its first-quarter 2026 results, reporting revenue of $706.6 million and diluted earnings per share of $4.28, both exceeding analyst estimates; however, the net book-to-bill ratio declined to 0.88x, attributed to the highest backlog cancellations in over a year, resulting in a significant stock plunge of approximately 23% in late April. On April 24, 2026, Seeking Alpha downgraded Medpace's stock from 'Strong Buy' to 'Buy' due to concerns over rising backlog cancellations and elevated direct costs. On May 2, 2026, Medpace raised its full-year 2026 guidance for revenue and GAAP net income. On May 31, 2026, the planned retirement of President Jesse Geiger was announced. Multiple class-action lawsuits have been filed against Medpace and certain officers, alleging securities fraud for the period of April 22, 2025, to February 9, 2026, claiming the company misled investors by understating cancellation rates and overstating its book-to-bill ratio.

The Contract Research Organization (CRO) industry generally experiences robust demand, driven by increasing research and development (R&D) spending and a growing trend of outsourcing clinical development. Medpace's business model, which focuses on small to mid-sized biopharmaceutical firms, makes it susceptible to fluctuations in capital markets and venture funding for biotech. The company has observed concerning trends in backlog cancellations, which have reached the upper range of what is considered normal, indicating potential volatility in future revenue streams. Despite these challenges, demand for Medpace's specialized clinical trial services, especially for oncology and rare disease development programs, remained resilient in Q1 2026.

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides comprehensive drug and medical device development services, operating in the Healthcare sector, specifically within the Diagnostics & Research and Laboratory Services industries. The company specializes in offering scientifically-driven outsourced clinical development services to biotechnology, pharmaceutical, and medical device companies, particularly focusing on small and mid-sized firms. Medpace's major services encompass full-service Phase I-IV clinical development, including study management, clinical monitoring, data management, and regulatory submissions. They also provide ancillary services such as bioanalytical laboratory services, imaging capabilities, global central laboratory, and a Phase I unit. The company possesses therapeutic expertise across various major areas, including oncology, cardiology, and central nervous system.

Headquartered in Cincinnati, Ohio, United States, Medpace has a significant global presence, employing approximately 6,300 people across 46 countries as of March 31, 2026. Its operations span the US, Europe, Asia, South America, Africa, and Australia, with regional offices and clinical sites across North America, Europe, Asia, and Latin America to support its global clinical trial operations.

In the past year, Medpace has maintained a reputation for reliable execution and deep medical expertise, with its "physician-led" approach differentiating it in the market. However, the company's reputation has been impacted by the recent securities fraud class action lawsuits, which allege that Medpace misled investors regarding cancellation rates and its book-to-bill ratio, leading to negative sentiment and increased legal exposure.

Medpace's ownership structure is characterized by a significant institutional presence and substantial insider holdings. Institutional investors collectively hold a dominant stake, ranging from approximately 74% to 85% of the outstanding shares, with major institutional owners including BlackRock, Inc., Vanguard Group Inc., and Aqr Capital Management Llc. Dr. August J. Troendle, the company's founder, CEO, and Chairman of the Board, is a major individual shareholder, holding approximately 18% to 22% of the outstanding shares.